|
Dr. Mark Miller did subspecialty training in Montreal at McGill University in the fields of Infectious Diseases and in Medical Microbiology and then pursued a Master’s degree in Epidemiology and Biostatistics. He has been a staff microbiologist and infectious disease specialist at the SMBD-Jewish General Hospital since 1993, where he has become the Chair of Infection Prevention and Control, the Chief of Microbiology, and the Head of the Division of Infectious Diseases. The bulk of his research has been in the epidemiology, prevention, and treatment of nosocomial infections, where he has described the rapid emergence of mupirocin resistance among MRSA, chaired the cross-Canada group studying the morbidity, health effects, and death rate from hospital-acquired C. difficile-associated diarrhea (CDAD), and headed the Canadian team which surveyed the reuse of single-use medical devices. He is currently studying CDAD in depth, including the recent epidemiology of severe CDAD in Canada, CDAD prevention using Lactobacillus probiotics, CDAD therapy with novel antibiotics and IVIG, and the use of laser-induced emissions for the ultra-rapid diagnosis of CDAD from stool samples. He also helped establish the Quebec province-wide guidelines for physicians, dentists, and other healthcare workers infected with blood-borne diseases and is the Chairman of the the Infection Control Working Group of McGill University, which harmonizes infection prevention and control practices in the Faculty of Medicine and in all McGill-affiliated health institutions. Has co-authored over 80 scientific publications and presented over 90 abstracts. He is a past-president of the Association of Medical Microbiology and Infectious Disease of Canada (AMMI-Canada), the professional society of over 500 Canadian physicians involved in the prevention, treatment, and research in the field of Infectious Diseases. He currently lives in Montreal, Canada.
|